keyword
https://read.qxmd.com/read/38456541/safety-and-quality-of-cystectomy-and-pelvic-lymph-node-dissection-after-neoadjuvant-durvalumab-and-cisplatin-gemcitabine
#21
JOURNAL ARTICLE
Luca Afferi, Martin Spahn, Stefanie Hayoz, Räto T Strebel, Sacha I Rothschild, Helge Seifert, Berna C Özdemir, Bernhard Kiss, Philipp Maletzki, Daniel Engeler, Gregory Wirth, Boris Hadaschik, Ilaria Lucca, Hubert John, Andreas Sauer, Michael Müntener, Lukas Bubendorf, Martina Schneider, Jana Musilova, Ulf Petrausch, Richard Cathomas
OBJECTIVE: To report on the surgical safety and quality of pelvic lymph node dissection (PLND) in patients treated with radical cystectomy (RC) and PLND for muscle-invasive bladder cancer (MIBC) after neoadjuvant chemo-immunotherapy. PATIENTS AND METHODS: The Swiss Group for Clinical Cancer Research (SAKK) 06/17 was an open-label single-arm phase II trial including 61 cisplatin-fit patients with clinical stage (c)T2-T4a cN0-1 operable urothelial MIBC or upper urinary tract cancer...
March 8, 2024: BJU International
https://read.qxmd.com/read/38454625/efficacy-and-safety-of-combination-neoadjuvant-chemo-hormonal-therapy-and-robot-assisted-radical-prostatectomy-for-oligometastatic-prostate-cancer
#22
JOURNAL ARTICLE
Makoto Kawase, Daiki Kato, Yuki Tobisawa, Koji Iinuma, Keita Nakane, Takuya Koie
No abstract text is available yet for this article.
March 7, 2024: International Journal of Urology: Official Journal of the Japanese Urological Association
https://read.qxmd.com/read/38449823/detection-of-sulfur-mustard-simulant-by-trisaryl-phosphoric-triamide-based-resin-using-a-quartz-crystal-microbalance-sensor
#23
JOURNAL ARTICLE
Jaeyoung Heo, Jin Hyun Park, Sun Gu Song, Seongwoo Lee, Seongyeop Lim, Chang Young Lee, Han Yong Bae, Changsik Song
Chemical warfare agents (CWAs) pose a persistent threat to human safety, and bis(2-chloroethyl) sulfide, or sulfur mustard (SM) is one of the most dangerous substances and is able to cause serious harm. Detecting SM gas is vital, but current methods have high-temperature requirements and limited selectivity, mainly because of the lack of CWA receptor development, and this makes them challenging to use. To address this issue, we present a trisaryl phosphoric triamide-based resin receptor that preferentially interacts with a SM simulant 2-chloroethyl ethyl sulfide (2-CEES) through dipole interactions...
February 29, 2024: RSC Advances
https://read.qxmd.com/read/38441850/a-multicenter-phase-ia-study-of-abgn-107-a-novel-antibody-drug-conjugate-in-patients-with-advanced-gastrointestinal-cancer
#24
MULTICENTER STUDY
Andrew H Ko, Andrew L Coveler, Benjamin L Schlechter, Tanios Bekaii-Saab, Brian M Wolpin, Jeffrey W Clark, Bruno Bockorny, Li-Yuan Bai, Yu-Chin Lin, Evelyn Chiang, Peter Langecker, Shih-Yao Lin
AbGn-107 is an antibody-drug conjugate directed against AG-7 antigen, a Lewis A-like glycol-epitope expressed in a variety of gastrointestinal (GI) malignancies. Based on promising antitumor activity of AbGn-107 in both in vitro and in vivo preclinical studies, we performed a GI cancer-specific Phase I trial. Standard 3 + 3 dose escalation was used evaluating intravenous doses ranging from 0.1 mg/kg every 4 weeks to 1.0 mg/kg every 2 weeks. Key eligibility included chemo-refractory locally advanced, recurrent, or metastatic gastric, colorectal, pancreatic, or biliary cancer, with ECOG PS 0-1; positive AG-7 expression was not required during dose escalation phase...
April 2024: Investigational New Drugs
https://read.qxmd.com/read/38425656/safety-and-feasibility-of-minimally-invasive-gastrectomy-after-neoadjuvant-immunotherapy-for-locally-advanced-gastric-cancer-a-propensity-score-matched-analysis-in-china
#25
JOURNAL ARTICLE
Hao Cui, Wenquan Liang, Jianxin Cui, Liqiang Song, Zhen Yuan, Lin Chen, Bo Wei
BACKGROUND: The effect of neoadjuvant immunotherapy on minimally invasive gastrectomy (MIG) for locally advanced gastric cancer (LAGC) remains controversial. This study aimed to compare short-term outcomes between MIG after neoadjuvant chemo-immunotherapy (NICT-MIG) and MIG after neoadjuvant chemotherapy alone (NCT-MIG), and determine risk factors for post-operative complications (POCs). METHODS: This retrospective study included clinicopathologic data from 193 patients who underwent NCT-MIG or NICT-MIG between January 2020 and February 2023 in the Department of General Surgery, Chinese People's Liberation Army General Hospital First Medical Center (Beijing, China)...
2024: Gastroenterology Report
https://read.qxmd.com/read/38410564/clinical-outcomes-of-the-robot-assisted-ivor-lewis-procedure-for-adenocarcinoma-of-the-esophagogastric-junction-with-semi-instrument-overlap-intrathoracic-anastomosis
#26
JOURNAL ARTICLE
Chuangui Chen, Biniam Kidane, Sofoklis Mitsos, Hongjing Jiang
BACKGROUND: The main difficulty of minimally invasive Ivor Lewis (IL) procedure for adenocarcinoma of the esophagogastric junction (AEGJ) is the intrathoracic esophagogastric anastomosis (IEA). We aimed to assess the safety and feasibility of the IL procedure with the da Vinci surgical system for treatment of AEGJ with semi-mechanical intrathoracic IEA. METHODS: The cohort included 72 patients with AEGJ who received treatment at the Department of Minimally Invasive Esophagus Surgery of the Tianjin Medical University Cancer Institute and Hospital from August 2020 to March 2023...
January 30, 2024: Journal of Thoracic Disease
https://read.qxmd.com/read/38410116/clinical-efficacy-of-plasmid-encoding-p62-sqstm1-elenagen-in-combination-with-gemcitabine-in-patients-with-platinum-resistant-ovarian-cancer-a-randomized-controlled-trial
#27
JOURNAL ARTICLE
Sergei Krasny, Yauheni Baranau, Sergey Polyakov, Ekaterina Zharkova, Olga Streltsova, Aliona Filimonava, Volha Siarheyeva, Sviatlana Kazlouskaya, Anton Khorau, Vladimir Gabai, Alexander Shneider
BACKGROUND: The purpose of this trial is to evaluate the safety and efficacy of ELENAGEN, a novel anticancer therapeutic DNA plasmid encoding p62/SQSTM1 protein, as an adjuvant to chemotherapy with gemcitabine (GEM) in patients with advanced platinum-resistant ovarian cancer. METHODS: This open-label prospective randomized study with two arms. GEM (1000 mg/m2 ) on days 1 and 8 every 3 weeks was administered in both arms: in the Chemo arm (n = 20), GEM was the only treatment, and in the ELENAGEN arm (n = 20), GEM was supplemented with ELENAGEN (2...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38396981/the-potential-role-of-probiotics-especially-butyrate-producers-in-the-management-of-gastrointestinal-mucositis-induced-by-oncologic-chemo-radiotherapy
#28
JOURNAL ARTICLE
Massimiliano Cazzaniga, Marco Cardinali, Francesco Di Pierro, Giordano Bruno Zonzini, Chiara Maria Palazzi, Aurora Gregoretti, Nicola Zerbinati, Luigina Guasti, Alexander Bertuccioli
Many clinical studies have now highlighted how the composition of the intestinal microbiota can regulate the effects of many oncological therapies. In particular, the modulation of microbial composition has been shown to enhance their efficacy and reduce potential side effects. Numerous adverse events induced by chemotherapy and radiotherapy appear to be strongly associated with an alteration in the intestinal microbiota caused by these treatments. This supports the hypothesis that the modulation or correction of the microbiota may decrease the toxic impact of therapies, improving patient compliance and quality of life...
February 15, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38390071/real-world-data-on-the-first-line-immune-checkpoint-inhibitors-or-in-combination-with-chemotherapy-in-older-patients-aged-%C3%A2-75-years-with-advanced-non-small-cell-lung-cancer
#29
JOURNAL ARTICLE
Panpan Zhang, Minting Ma, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Di Wu, Xiaoling Chen, Xiangjuan Ma, Guangming Tian, Sen Han, Jieran Long, Yang Wang, Ziran Zhang, Qianyun Hao, Jian Fang
PURPOSE: The purpose of this study is to investigate the efficacy and safety of immune checkpoint inhibitors (ICIs) or plus with chemotherapy in older patients. METHODS: We enrolled 110 older patients with non-small cell lung cancer (NSCLC ≥75 years) who received either chemotherapy alone (chemo), ICI plus chemotherapy (ICI + chemo), or ICI alone and ICI plus other therapies, which included anti-angiogenesis drugs or other novel ICI (ICIs). Patient characteristics, treatment response, survival, and toxicity were evaluated...
February 29, 2024: Heliyon
https://read.qxmd.com/read/38387811/disease-control-and-late-toxicity-in-adaptive-dose-painting-by-numbers-versus-nonadaptive-radiation-therapy-for-head-and-neck-cancer-a-randomized-controlled-phase-2-trial
#30
JOURNAL ARTICLE
Aurélie De Bruycker, Wilfried De Neve, Jean-François Daisne, Tom Vercauteren, Werner De Gersem, Luiza Olteanu, Dieter Berwouts, Stéphanie Deheneffe, Indira Madani, Ingeborg Goethals, Fréderic Duprez
PURPOSE: Local recurrence remains the main cause of death in stage III-IV nonmetastatic head and neck cancer (HNC), with relapse-prone regions within high 18 F-fluorodeoxyglucose positron emission tomography (18 F-FDG-PET)-signal gross tumor volume. We investigated if dose escalation within this subvolume combined with a 3-phase treatment adaptation could increase local (LC) and regional (RC) control at equal or minimized radiation-induced toxicity, by comparing adaptive 18 F-FDG-PET voxel intensity-based dose painting by numbers (A-DPBN) with nonadaptive standard intensity modulated radiation therapy (S-IMRT)...
February 21, 2024: International Journal of Radiation Oncology, Biology, Physics
https://read.qxmd.com/read/38378398/transitioning-to-neoadjuvant-therapy-for-resectable-non-small-cell-lung-cancer-trends-and-surgical-outcomes-in-a-regionalized-pulmonary-oncology-network
#31
JOURNAL ARTICLE
Yohann Pilon, Merav Rokah, Joseph Seitlinger, Boris Sepesi, Roni F Rayes, Jonathan Cools-Lartigue, Sara Najmeh, Christian Sirois, David Mulder, Lorenzo Ferri, Bassam Abdulkarim, Nicole Ezer, Richard Fraser, Sophie Camilleri-Broët, Pierre-Olivier Fiset, Annick Wong, Shelly Sud, Adrian Langleben, Jason Agulnik, Carmela Pepe, Benjamin Shieh, Vera Hirsh, Linda Ofiara, Scott Owen, Jonathan D Spicer
BACKGROUND: Several regulatory agencies have approved the use of the neoadjuvant chemo-immunotherapy for resectable stage II and III of non-small cell lung cancer (NSCLC) and numerous trials investigating novel agents are underway. However, significant concerns exist around the feasibility and safety of offering curative surgery to patients treated within such pathways. The goal in this study was to evaluate the impact of a transition towards a large-scale neoadjuvant therapy program for NSCLC...
December 19, 2023: Clinical Lung Cancer
https://read.qxmd.com/read/38369892/role-of-phytoconstituents-in-cancer-treatment-a-review
#32
JOURNAL ARTICLE
Manish Kumar, Sakshi Gupta, Kamini Kalia, Dharmendra Kumar
Over the years, natural compounds have become a significant advancement in cancer treatment, primarily due to their effectiveness, safety, bio-functionality, and wide range of molecular structures. They are now increasingly preferred in drug discovery due to these attributes. These compounds, whether occurring naturally or with synthetic modifications, find applications in various fields like biology, medicine, and engineering. While chemotherapy has been a successful method for treating cancer, it comes with systemic toxicity...
January 26, 2024: Recent Adv Food Nutr Agric
https://read.qxmd.com/read/38319556/protective-efficacy-and-safety-of-radiation-attenuated-and-chemo-attenuated-plasmodium-falciparum-sporozoite-vaccines-against-controlled-and-natural-malaria-infection-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#33
REVIEW
Mohamed T Abuelazm, Mohamed A Elzeftawy, Manar Ahmed Kamal, Helmy Badr, Mohamed Gamal, Mahmoud Aboulgheit, Basel Abdelazeem, Sherief Abd-Elsalam, Mohamed Abouzid
BACKGROUND AND OBJECTIVE: Despite the significant burden of Plasmodium falciparum (Pf) malaria and the licensure of two vaccines for use in infants and young children that are partially effective in preventing clinical malaria caused by Pf, a highly effective vaccine against Pf infection is still lacking. Live attenuated vaccines using Pf sporozoites as the immunogen (PfSPZ Vaccines) hold promise for addressing this gap. Here we review the safety and efficacy of two of the most promising PfSPZ approaches: PfSPZ Vaccine (radiation attenuated PfSPZ) and PfSPZ-CVac (chemo-attenuated PfSPZ)...
February 6, 2024: Infection
https://read.qxmd.com/read/38298433/a-pilot-study-on-the-safety-and-efficacy-of-neoadjuvant-chemo%C3%A2-adoptive-immunotherapy-for-locally-advanced-rectal-cancer
#34
JOURNAL ARTICLE
Yu Okazawa, Takashi Kamigaki, Kiichi Sugimoto, Takeshi Yamada, Yoichiro Yoshida, Sachiko Okada, Hiroshi Ibe, Eri Oguma, Takuma Iwai, Akihisa Matsuda, Teppei Yamada, Suguru Hasegawa, Shigenori Goto, Rishu Takimoto, Kazuhiro Sakamoto
The safety and efficacy of combination therapy of immune cell therapy and chemotherapy [chemo-adoptive immunotherapy (CAIT)] for patients with stage IV or recurrent colorectal cancer have been reported. In the present study, the safety and efficacy of neoadjuvant CAIT were investigated for preoperative therapy of locally advanced rectal cancer. The study included patients with cT3/T4 or cN (+) rectal adenocarcinoma scheduled for curative surgery. Six patients who consented to participate in the current study were selected as subjects...
March 2024: Oncology Letters
https://read.qxmd.com/read/38275022/disulfiram-a-novel-repurposed-drug-for-cancer-therapy
#35
JOURNAL ARTICLE
Min Zeng, Baibei Wu, Wenjie Wei, Zihan Jiang, Peiqiang Li, Yuanting Quan, Xiaobo Hu
Cancer is a major global health issue. Effective therapeutic strategies can prolong patients' survival and reduce the costs of treatment. Drug repurposing, which identifies new therapeutic uses for approved drugs, is a promising approach with the advantages of reducing research costs, shortening development time, and increasing efficiency and safety. Disulfiram (DSF), an Food and Drug Administration (FDA)-approved drug used to treat chronic alcoholism, has a great potential as an anticancer drug by targeting diverse human malignancies...
January 26, 2024: Chinese Medical Journal
https://read.qxmd.com/read/38261438/oral-glutamine-is-there-a-role-in-the-amelioration-of-radiation-induced-mucositis-a-prospective-case-control-study-at-a-tertiary-care-centre-in-north-india
#36
JOURNAL ARTICLE
Kaneez Fatima, Asifa Andleeb, Shahida Nasreen, Mushtaq A Sofi, Arshad M Najmi, Sumyra K Qadri, Rubyiya Ryhan, Shagufta Roohi, Fir Afroz, Nazir A Khan
BACKGROUND: The most frequently occurring painful and dose-limiting side effect of radiation therapy (RT) to the head and neck region is oral mucositis (OM). Several studies demonstrated that glutamine may reduce the severity and the duration of OM significantly during RT and chemo-radiotherapy in patients with head and neck cancer (HNC). MATERIALS AND METHODS: Between January 2021 and August 2022, a prospective single institutional case-control study compared the efficacy and safety of oral glutamine on radiation-induced mucositis in patients with HNC...
January 22, 2024: Journal of Cancer Research and Therapeutics
https://read.qxmd.com/read/38257677/disclosing-fast-detection-opportunities-with-nanostructured-chemiresistor-gas-sensors-based-on-metal-oxides-carbon-and-transition-metal-dichalcogenides
#37
REVIEW
Michele Galvani, Sonia Freddi, Luigi Sangaletti
With the emergence of novel sensing materials and the increasing opportunities to address safety and life quality priorities of our society, gas sensing is experiencing an outstanding growth. Among the characteristics required to assess performances, the overall speed of response and recovery is adding to the well-established stability, selectivity, and sensitivity features. In this review, we focus on fast detection with chemiresistor gas sensors, focusing on both response time and recovery time that characterize their dynamical response...
January 17, 2024: Sensors
https://read.qxmd.com/read/38242720/ipilimumab-and-nivolumab-combined-with-anthracycline-based-chemotherapy-in-metastatic-hormone-receptor-positive-breast-cancer-a-randomized-phase-2b-trial
#38
RANDOMIZED CONTROLLED TRIAL
Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur, Bjørnar Gilje, Beate Boge, Andrea Gombos, Ragnhild Sørum Falk, Randi R Mathiesen, Lars Julsrud, Øystein Garred, Hege G Russnes, Ragnhild Reehorst Lereim, Sudhir Kumar Chauhan, Ole Christian Lingjærde, Claire Dunn, Bjørn Naume, Jon Amund Kyte
BACKGROUND: Immune checkpoint inhibitors have shown minimal clinical activity in hormone receptor-positive metastatic breast cancer (HR+ mBC). Doxorubicin and low-dose cyclophosphamide are reported to induce immune responses and counter regulatory T cells (Tregs). Here, we report the efficacy and safety of combined programmed cell death protein-1/cytotoxic T-lymphocyte-associated protein 4 blockade concomitant with or after immunomodulatory chemotherapy for HR+ mBC. METHODS: Patients with HR+ mBC starting first-/second- line chemotherapy (chemo) were randomized 2:3 to chemotherapy (pegylated liposomal doxorubicin 20 mg/m2 every second week plus cyclophosphamide 50 mg by mouth/day in every other 2-week cycle) with or without concomitant ipilimumab (ipi; 1 mg/kg every sixth week) and nivolumab (nivo; 240 mg every second week)...
January 19, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38237696/the-efficacy-of-tradipitant-in-patients-with-diabetic-and-idiopathic-gastroparesis-in-a-phase-3-randomized-placebo-controlled-clinical-trial
#39
JOURNAL ARTICLE
Jesse L Carlin, Christos Polymeropoulos, Michael Camilleri, Anthony Lembo, Michaela Fisher, Caleigh Kupersmith, Darby Madonick, Paula Moszczynski, Sandra Smieszek, Changfu Xiao, Gunther Birznieks, Mihael H Polymeropoulos
BACKGROUND: Neurokinin receptor 1 antagonists are effective in reducing nausea and vomiting in chemotherapy-induced emesis. We investigated the safety and efficacy of tradipitant, a neurokinin receptor 1 antagonist, in patients with idiopathic and diabetic gastroparesis. METHODS: A total of 201 adults with gastroparesis were randomly assigned to oral tradipitant 85 mg (n = 102) or placebo (n = 99) twice daily for 12 weeks. Symptoms were assessed by a daily symptom dairy, Gastroparesis Cardinal Symptom Index scores, and other patient-reported questionnaires...
January 17, 2024: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/38229578/a-potent-multifunctional-zif-8-nanoplatform-developed-for-colorectal-cancer-therapy-by-triple-delivery-of-chemo-radio-targeted-therapy-agents
#40
JOURNAL ARTICLE
Sonia Iranpour, Ahmad Reza Bahrami, Mahdieh Dayyani, Amir Sh Saljooghi, Maryam M Matin
BACKGROUND: Multimodal cancer therapy has garnered significant interest due to its ability to target tumor cells from various perspectives. The advancement of novel nano-delivery platforms represents a promising approach for improving treatment effectiveness while minimizing detrimental effects on healthy tissues. METHODS: This study aimed to develop a multifunctional nano-delivery system capable of simultaneously delivering an anti-cancer drug, a radiosensitizer agent, and a targeting moiety (three-in-one) for the triple combination therapy of colorectal cancer (CRC)...
January 17, 2024: Journal of Materials Chemistry. B, Materials for Biology and Medicine
keyword
keyword
104142
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.